REAL-WORLD UTILIZATION AND DISCONTINUATION PATTERNS OF PCSK9 INHIBITOR USE AT A LARGE, COMMUNITY-BASED LIPID CLINIC

Abstract

PCSK9 inhibitor (PCSK9i) use continues to rise; however, access is limited. Herein, we describe our experience at a cardiology-based community lipid clinic with a focus on payer origin and intolerance rates. Queries for the clinic population on PCSK9i use were performed using the “Slicer-Dicer